Scandion Oncology: Strengthened Management
Redeye supports Scandion appointing Johnny Stilou as new CFO. Johnny Stilou has extensive CFO experience, giving us confidence that he will competently guide Scandion's capital market strategy. Further, we judge his experience and network will benefit the company in negotiating a potential licensing/partnership deal following SCO-101 phase II trials. Current CFO Carit Jacques Andersen will stay on during a transitional period before leaving the company.
Overall, we view this transition in management positively, facilitating Scandion's journey through clinical-stage and beyond..